"ErbB Receptors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A family of structurally-related cell-surface receptors that signal through an intrinsic PROTEIN-TYROSINE KINASE. The receptors are activated upon binding of specific ligands which include EPIDERMAL GROWTH FACTORS, and NEUREGULINS.
| Descriptor ID |
D066246
|
| MeSH Number(s) |
D08.811.913.696.620.682.725.400.009 D12.776.543.750.630.009 D12.776.543.750.750.400.074
|
| Concept/Terms |
ErbB Receptors- ErbB Receptors
- Receptors, ErbB
- Receptors, Epidermal Growth Factor-Urogastrone
- Receptors, Epidermal Growth Factor Urogastrone
- Receptors, Epidermal Growth Factor
- EGF Receptors
- Receptors, EGF
- Epidermal Growth Factor Receptor Family Proteins
- HER Family Receptors
- Family Receptors, HER
- Receptors, HER Family
- Erb-b2 Receptor Tyrosine Kinases
- Erb b2 Receptor Tyrosine Kinases
|
Below are MeSH descriptors whose meaning is more general than "ErbB Receptors".
Below are MeSH descriptors whose meaning is more specific than "ErbB Receptors".
This graph shows the total number of publications written about "ErbB Receptors" by people in this website by year, and whether "ErbB Receptors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 11 | 6 | 17 |
| 1995 | 10 | 1 | 11 |
| 1996 | 14 | 6 | 20 |
| 1997 | 13 | 3 | 16 |
| 1998 | 12 | 5 | 17 |
| 1999 | 7 | 8 | 15 |
| 2000 | 16 | 7 | 23 |
| 2001 | 15 | 5 | 20 |
| 2002 | 14 | 6 | 20 |
| 2003 | 26 | 8 | 34 |
| 2004 | 34 | 14 | 48 |
| 2005 | 23 | 22 | 45 |
| 2006 | 33 | 24 | 57 |
| 2007 | 49 | 28 | 77 |
| 2008 | 36 | 26 | 62 |
| 2009 | 26 | 42 | 68 |
| 2010 | 40 | 34 | 74 |
| 2011 | 34 | 33 | 67 |
| 2012 | 28 | 25 | 53 |
| 2013 | 35 | 13 | 48 |
| 2014 | 19 | 15 | 34 |
| 2015 | 31 | 22 | 53 |
| 2016 | 22 | 23 | 45 |
| 2017 | 13 | 18 | 31 |
| 2018 | 2 | 30 | 32 |
| 2019 | 3 | 28 | 31 |
| 2020 | 3 | 36 | 39 |
| 2021 | 3 | 17 | 20 |
| 2022 | 1 | 28 | 29 |
| 2023 | 0 | 18 | 18 |
| 2024 | 0 | 3 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "ErbB Receptors" by people in Profiles.
-
Antibody-Conjugated Polymersomes with Encapsulated Indocyanine Green J-Aggregates and High Near-Infrared Absorption for Molecular Photoacoustic Cancer Imaging. ACS Appl Mater Interfaces. 2024 Feb 07; 16(5):5598-5612.
-
Integrative genomic analyses reveal putative cell type-specific targets of the Drosophila ets transcription factor Pointed. BMC Genomics. 2024 Jan 23; 25(1):103.
-
Sotorasib with panitumumab in chemotherapy-refractory KRASG12C-mutated colorectal cancer: a phase 1b trial. Nat Med. 2024 Jan; 30(1):265-270.
-
Rapid detection of mutations in CSF-cfTNA with the Genexus Integrated Sequencer. J Neurooncol. 2024 Jan; 166(1):39-49.
-
Biomarker Testing in Patients With Unresectable Advanced or Recurrent Non-Small Cell Lung Cancer. JAMA Netw Open. 2023 Dec 01; 6(12):e2347700.
-
ATM Mutations Associate with Distinct Co-Mutational Patterns and Therapeutic Vulnerabilities in NSCLC. Clin Cancer Res. 2023 12 01; 29(23):4958-4972.
-
Real-World Efficacy and Safety of Amivantamab for EGFR-Mutant NSCLC. J Thorac Oncol. 2024 Mar; 19(3):500-506.
-
EGFR Tyrosine Kinase Inhibitors for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Podcast. Target Oncol. 2023 Nov; 18(6):807-817.
-
HER4 and EGFR Activate Cell Signaling in NRG1 Fusion-Driven Cancers: Implications for HER2-HER3-specific Versus Pan-HER Targeting Strategies. J Thorac Oncol. 2024 01; 19(1):106-118.
-
A phase I trial of the pan-ERBB inhibitor neratinib combined with the MEK inhibitor trametinib in patients with advanced cancer with EGFR mutation/amplification, HER2 mutation/amplification, HER3/4 mutation or KRAS mutation. Cancer Chemother Pharmacol. 2023 08; 92(2):107-118.